Regorafenib (Onyx/Bayer) in Phase GRID study for GIST

Results were announced by Onyx Pharma/Bayer Healthcare from the Phase III trial GRID (GIST - Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506 for the treatment of patients with metastatic and/or unresectable Gastrointestinal Stromal Tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib. The trial met its primary endpoint of statistically significant improvement in progression-free survival. In this trial, the safety and tolerability of regorafenib were consistent with what was seen in earlier studies. Data from the study are expected to be presented at an upcoming scientific meeting